Research programme: nanoantibodies - Allele Biotechnology and Pharmaceuticals
Alternative Names: Anti-CoV2 nanoantibodies - Allele Biotechnology and PharmaceuticalsLatest Information Update: 28 Oct 2024
At a glance
- Originator Allele Biotechnology and Pharmaceuticals
- Class Single-domain antibodies; Viral vaccines
- Mechanism of Action Immunostimulants; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Inhalation)
- 28 Oct 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in USA (Inhalation)
- 01 Sep 2020 Early research in COVID-2019 infections (Prevention) in USA (Inhalation) before September 2020